Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 43.44 | 22.81 | 1.82 | -15.16 |
Depreciation | -9.12 | -8.95 | -3.66 | -3.25 |
Tax paid | -8.77 | -1.47 | -2.86 | 0 |
Working capital | 33.97 | -80.01 | -110.8 | 56.46 |
Other operating items | ||||
Operating | 59.51 | -67.61 | -115.51 | 38.04 |
Capital expenditure | 3.56 | 61.69 | -199.12 | 43.73 |
Free cash flow | 63.07 | -5.92 | -314.63 | 81.77 |
Equity raised | 1,784.26 | 1,715.98 | 1,706.88 | 2,367.93 |
Investing | -72.53 | 71.05 | -204.05 | -6.44 |
Financing | -29.41 | 35.07 | -87.19 | 38.6 |
Dividends paid | 0 | 0 | 4.84 | 0 |
Net in cash | 1,745.4 | 1,816.18 | 1,105.86 | 2,481.85 |
Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice